AbbVie stock nears its record high after a quarterly beat
AD HOC NEWS
AbbVie stock (ABBV) is approaching its 52-week high after reporting strong Q2 2026 earnings, beating analyst consensus for both EPS and revenue. The company's revenue increased by 10.2% year-over-year, and analysts maintain a "Moderate Buy" consensus with price targets above the current stock price. AbbVie has also provided Q3 2026 EPS guidance, which will be the next key metric for investors.
Read the full story
This is a short summary. The complete article is published by AD HOC NEWS.
Headline and summary aggregated from public news feeds. For information only — not financial advice.